drastically lower, at less than 5%. 5 In contrast with B. burgdorferi infection in humans, 95% of dogs infected with B. burgdorferi do not develop clinical illness. 6 Clinical signs of B. burgdorferi infection in dogs can include polyarthritis, pyrexia, lethargy, anorexia, and lymphade-
nopathy. An association between B. burgdorferi infection and fatal glomerulonephropathy has been suggested, but a causal link has not been established. 7, 8 The most commonly used methods for prevention of B. burgdorferi infection in dogs include tick avoidance, prevention of tick infestation using acaricides, and vaccination. The primary limitation of many acaricides is that they might not offer complete protection if they target only the adult stage of ticks; meanwhile, nymphs (immature ticks) are also capable of transmitting B. burgdorferi.
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Another potential drawback with acaricides is that most require monthly reapplication/administration, which could reduce owner compliance and thus product efficacy. Vaccination offers an alternative approach to prevention of disease, but efficacy is unclear with efficacies ranging from 50% to 100%. [10] [11] [12] [13] Lyme disease is a concern for pet owners and veterinarians in North America. Our primary objective was to investigate the efficacy of vaccines for the prevention of Lyme disease in dogs in North
America. This article was prepared in accordance with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. 14 
| METHODS

| Protocol and registration
The intended search strategy, eligibility criteria, study selection, data collection process, assessment of risk of bias, and the approach used for synthesis were included in the protocol published in advance, which is available online from SYREAF (systematic reviews for animals and food) and the University of Guelph Atrium, at: http://hdl.handle.
net/10214/10049.
| Eligibility criteria
A summary of inclusion and exclusion criteria can be found in Table 1 .
The population of interest included pet dogs in Canada and the United
States. Mexico was excluded because it is uncertain whether Lyme disease is endemic in this region. 15, 16 For the intervention, studies that reported the use of a canine B. burgdorferi vaccine were eligible.
Vaccines used outside North America were not eligible, because additional species of Borrelia other than B. burgdorferi are responsible for Lyme disease on other continents; vaccines used to control Lyme disease in those regions might not be relevant to the North American population of dogs. Since the 1st published report of Lyme disease in dogs appeared in 1984, only studies published in 1984 or later were eligible for inclusion. 17 Eligible study designs included primary research studies using experimental (natural or deliberate disease challenge) and analytical observational study designs. The latter type of study design was considered eligible, as these studies approximate real-life exposure to Lyme disease.
Eligible studies had to include outcomes assessing at least 1 of 2 measures of vaccine efficacy:
• reduction of incidence of clinical illness after exposure to B. burgdorferi (critical outcome) and
• reduction of incidence of seroconversion after exposure to
B. burgdorferi (noncritical outcome).
Critical outcomes represented clinical outcomes that are relevant to practitioners and pet owners. Critical outcomes were modified slightly from the protocol, so that all dogs that were exposed to B. burgdorferi were assessed for clinical signs, rather than only dogs confirmed with B. burgdorferi infection. Without a reliable disease model for Lyme disease in the dog and no gold standard test for determining infection status, it was determined that infection status could not reliably be determined; thus, exposure to B. burgdorferi was considered sufficient. 18 Although the protocol stated that noncritical outcomes would be assessed for both types of study designs (ie, experimental and observational), they were not assessed for b Noncritical outcomes were defined as the "incidence of infection given exposure" in our protocol.
experimental study designs for the above reasons and because there was considerable diversity in the methods used to determine the infection status, which would prevent combination of these data. In order to combine these data in a meta-analysis, there need to be a basis for preferring one method over the other; also, in the absence of a gold standard, this cannot be accomplished. With limited options for determining infection status under field conditions, seroconversion was assessed as a noncritical outcome in observational studies. 19, 20 Although adverse effects were not strictly considered an outcome measure, they were recorded. 
| Information sources
| Search
The search strategy comprised 3 concepts: canine, vaccine, and borreliosis. The search strategy used to identify relevant articles in MED-LINE was as follows: 
| Study selection
Search results were loaded into EndNote, and duplicates were removed. The search results were then loaded into an online systematic review program (Distiller SR, Ottawa, ON, Canada), and additional duplicates were removed using Distiller SR. Primary reviewers were veterinarians with postgraduate training in epidemiology and the methodology of systematic reviews. Before screening and data extraction, primary reviewers received training to ensure consistency.
Screening and data extraction were performed independently by 2 reviewers using pretested forms. Level 1 screening was performed on titles and abstracts using 3 questions:
1. "Does the title and/or abstract describe primary research?"
2. "Does the title and/or abstract describe dogs being used as the study subjects?" 5. What kind of study design was used?
6. Did the study include a concurrent comparator group (either a control group or placebo group)?
7. Did the study evaluate a measure of vaccine effect (ie, reduction of incidence of clinical illness after exposure or reduction of incidence of seroconversion after exposure)?
Question 5 was modified from "is the study design eligible?" in the protocol to "what kind of study design was used?" in order to streamline the data extraction process, so that references could be diverted to the appropriate form at this stage and thus minimize conflicts during data extraction. Articles for which the answers to questions 4, 6, and 7 were "yes" moved forward to data extraction. An additional revision to the protocol was made: conference proceedings were excluded during Level 2 screening because they represent a lower quality of evidence and might have posed issues with data extraction and risk of bias assessment because of a lack of detail in short documents. At all stages of screening, disagreements between reviewers were resolved by consensus, and no arbitrator was needed.
| Data collection process
Conflicts during data extraction were resolved by consensus. Authors of eligible studies were contacted for additional unpublished work, and responses received within 1 month were included.
| Data items
For each study, study characteristics extracted were geographic location (country, province/state), season, and year of publication.
The month and year of study initiation and conclusion were extracted, rather than extracting study duration (as stated in the protocol dogs were considered to be in separate treatment groups if a different vaccine dose was used, which was a modification to the protocol.
Commercial availability of the vaccine was extracted only for observational studies, instead of all studies, as stated in the protocol.
It was determined that commercial availability was not relevant for challenge trials because a vaccine that was commercially available at the time of the trial might have different active ingredients compared to the currently commercially available version of the vaccine. The most useful measure of commercial availability in challenge trials would be to link previous studies with currently commercially available vaccines; however, this information was unavailable and potentially could not be verified because of proprietary rights of vaccine companies.
A summary of critical and noncritical outcomes extracted can be found in Table 2 . Seroconversion, a noncritical outcome, was 
| Risk of bias in individual studies
Risk of bias assessment was performed at the outcome level Risk of bias in experimental studies was assessed using the Cochrane Collaboration's Risk of Bias tool. 22 Domains assessed were selection, performance, detection, attrition, reporting, and other bias.
The judgment outcome options included low, high, and unclear risk of bias. The risk of bias regarding randomization was modified from the Cochrane tool because of the anticipated level of reporting in the veterinary literature; the risk of bias was low as long as the authors stated that randomization was used to allocate animals to intervention groups, even if the study did not report further details regarding the method of randomization. If the authors did not state whether or not randomization was used, the risk of bias was unclear. The risk of bias for this domain was high if authors stated that animals were assigned to groups in a manner which did not include a formal random process.
For trials with multiple intervention groups, the risk of bias assessment was performed at the trial level, as the methods did not vary among different intervention groups.
| Summary measures
Raw data were extracted, as none of the studies reported effect sizes. Noncritical outcomes were defined as the "incidence of infection given exposure" in our protocol.
| Synthesis of results
Observational studies and experimental studies were analyzed separately. For critical outcomes, a separate random effects meta-analysis was performed for each clinical sign independently. All meta-analyses were performed at the trial level using R Statistical Software and the "metafor" package. 23, 24 A meta-analysis was only performed if at least 3 trials were eligible. Effect sizes were calculated as odds ratios (ORs) using raw data and the "escalc" command. A multilevel model was built using the "rma.mv" command and the restricted maximum likelihood method, including trial as a random effect to account for multiple trials within a publication. For studies that used the same control group for multiple treatment groups, these treatment groups were kept separate only if there was an a priori difference identified for potential subsequent subgroup analyses (ie, different vaccine doses or different challenge). To account for the use of the same control group in these multiple treatment arm studies, an approximate adjustment was made, 25 an additional random effect was added to account for within-study clustering, and calculation of the covariance among sampling errors was performed before model building to account for correlation between different OR estimates using the same control group. 26 Trials in which there were zero cases of clinical signs in both intervention and comparator groups were included in the metaanalysis by using a continuity correction factor of 0.5. To obtain a measure of heterogeneity, I 2 was manually computed in R. 27 See Supplemental Information for R code.
| Risk of bias across studies
Funnel plots were used to evaluate publication bias provided that at least 10 trials were included in a meta-analysis.
| Additional analyses
None of the intended subgroup analyses were performed because of low heterogeneity.
3 | RESULTS
| Study selection
Results for the total number of articles screened, assessed for eligibility, included in the review, and excluded from the review, along with reasons for exclusion at Level 2, are presented in Figure 1 . 
| Study characteristics
The results for the characteristics of the 16 articles are presented in Table 3 (observational) and Table 4 (challenge studies). Among observational studies, 1 cohort study was identified and the remaining 2 studies were cross-sectional. None of the challenge studies reported the month or year of study initiation or termination. Most challenge studies induced disease using an infected tick challenge and tested puppies younger than 6 months of age. Various doses of bacterins and recombinant vaccines were used among challenge studies (Table 4 ).
| Risk of bias within studies
Results for the risk of bias among experimental studies are presented in Figure 2 . Although the risk of bias assessment was performed at the outcome level for each trial (eg, lameness outcome), the results are presented at the publication level for ease of interpretation, because the results did not differ between outcomes and trials. None of the challenge trials indicated that methods were used to ensure allocation concealment or blinding of personnel. Although many experimental studies were classified as a "low" risk of bias for random sequence generation because they stated that dogs were randomly assigned to an intervention group, only 1 study specified the actual method used to randomly assign dogs to an intervention group. 38 For all 3 observational studies, the risk of bias owing to confounding was judged to be "critical," because none of the studies accounted for the use of tick preventives. Selection bias in both cross-sectional observational studies was judged as "serious" because all dogs included in the study were selected for inclusion because they presented for heartworm testing. For the cohort observational study, there was no information on which to base a judgment for the selection of dogs into the study or the measurement of outcomes (it is unknown whether dog owners or veterinarians assessed dogs for clinical signs). In addition, the cohort study did not provide information regarding inclusion or exclusion criteria for control dogs; therefore, no judgment could be made in the domain of classification of interventions. Bias in the classification of interventions, bias because of deviation from intended interventions, bias in the measurement of outcomes, and bias because of selective reporting were all judged to be "low" for both cross-sectional observational studies. Bias because of missing data was judged as "moderate" for both cross-sectional observational studies as there was no information about which dogs were excluded from the analysis. Bias because of deviations from intended interventions, missing data, and selective reporting were judged as "low" for the cohort observational study.
| Results of individual studies
A summary of study results for included observational studies is presented in Table 3 . Only 1 observational study (cohort study design) assessed clinical signs, but because these were grouped together, data for individual clinical signs could not be extracted. This observational study did not assess seroconversion after vaccination; therefore, raw data could not be extracted for that noncritical outcome. The other 2 observational studies (cross-sectional study design) provided raw data for seroconversion between vaccinated and unvaccinated dogs.
A summary of study results for 17 included challenge trials from 13 publications is presented in Table 4 . At least 1 critical outcome was assessed in 16 of the 17 trials. Sixteen challenge trials assessed lameness, 7 evaluated anorexia, 5 assessed pyrexia, 6 assessed depression, and none assessed lymphadenopathy.
According to 4 studies that included information about adverse events, serious adverse events were uncommon. Three of these studies noted mild swelling and reddening at the injection site. 1, 30, 32 One of these studies reported that 8 of 10 dogs had a slight swelling at the injection site at the 1st vaccination and 3 of the 10 dogs had a similar reaction at the 2nd vaccination. 32 One observational study reported that 38 of 1969 dogs (1.9%) had minor reactions, and that 1 dog had a reaction after the 2nd vaccine dose; all reactions were reported to have resolved without complications by 72 hours after vaccination. 28 No further details were provided as to the type of clinical signs observed during these minor reactions. 28 
| Synthesis of results
Only 2 observational studies provided sufficient raw data for the noncritical outcome; therefore, we did not perform a meta-analysis among observational studies, because at least 3 studies were required to perform a meta-analysis. 
| Risk of bias across studies
A funnel plot was generated for the lameness outcome only. Publication bias could not be assessed for the remaining critical outcomes because there were 7 or fewer trials in each respective meta-analysis.
Based on the funnel plot for the lameness outcome, publication bias was possible because the lower left corner of the funnel contained no studies ( Figure 7 ). However, it should be noted that sample sizes were small, with more than half of trials having 10 dogs or less per treatment group.
| Additional analysis
Subgroup analyses were not performed because of low heterogeneity.
4 | DISCUSSION
| Summary of evidence
There was consistency in the direction of the estimated summary ORs for lameness, anorexia, pyrexia, and depression outcomes, with all estimates less than 1. Although the confidence intervals were wide Could not extract raw data because serological response was not assessed after vaccination. Could not extract critical outcomes because clinical signs were grouped together. Each row in the table corresponds to 1 trial. Separate trials from the same publication are indicated by letters a, b and c. Trials with multiple treatment groups are presented in the same row. Study authors reported that 2 dogs were lame in the treatment group but did not attribute the lameness to infection with B. burgdorferi because spirochetes were not recovered and serologic evidence of B. burgdorferi infection or exposure not detected. We include these dogs as positives here because the odds of lameness unrelated to B. burgdorferi infection should be equal in both treatment and control groups.
for these individual studies, all intervals for the summary estimates were less than the null value of 1, except for the anorexia outcome.
There was low heterogeneity for all critical outcomes (suggesting relatively consistent results across studies). Overall, the consistency in directionality between different clinical outcomes, despite wide confidence intervals, suggests that vaccination reduces the odds of clinical signs in vaccinated dogs compared to control dogs.
However, several issues relating to the assumption that all study dogs were exposed to B. burgdorferi were identified among these challenge studies. Most challenge studies tested only a subsample of ticks to determine the proportion of ticks infected with B. burgdorferi and then extrapolated this proportion to the population of ticks used to infect the study population of dogs (data not shown). The proportion of ticks infected with B. burgdorferi was often as low as 35%-40% in many of the challenge studies and ranged from 24% to 100%.
Researchers tried to overcome this difficulty by ensuring that several ticks fed on each dog, but this effort does not guarantee that all dogs in each group were exposed to B. burgdorferi. Although the resulting misclassification of dogs with respect to B. burgdorferi exposure status would be non-differential between vaccinated and control dogs, differences in exposure might be magnified by small samples sizes, and the low frequency of clinical signs in dogs infected with B. burgdorferi.
Conclusions drawn from our meta-analyses depend on the assumption that dogs in both the vaccinated and comparator groups were equally exposed to B. burgdorferi and had an equal likelihood of developing clinical signs under the null hypothesis. In future studies, this important assumption could be verified by testing all ticks to demonstrate that each dog was exposed to B. burgdorferi.
No overall assessment of risk of bias for each observational study was performed. Because of our modification from the Cochrane tool, our risk of bias assessment was lenient for the category of random allocation; we assessed the risk as "low" if the authors stated that random allocation was performed; however, further information about the method of random allocation is required to adequately assess whether this step was performed well or not. Although none of the challenge studies reported allocation concealment, this is unlikely to The information provided in this review will be useful for both practicing veterinarians and researchers. Not only will this review help to guide clinical decision-making, but it also provides valuable information regarding improvements in study design for researchers and has revealed important gaps in the literature. To date, limited research has been performed in field conditions (with natural disease exposure), and we were unable to perform a meta-analysis for observational studies because of an insufficient number of studies. Although we were able to perform several meta-analyses with challenge 
| Limitations
Incomplete retrieval of identified research is an unlikely source of bias for this systematic review, as we were able to retrieve all relevant articles identified in the electronic databases. However, we cannot rule out the existence of unpublished studies performed by vaccine companies, which would have been eligible for inclusion. Because of proprietary rights of vaccine companies, these records might not be publicly available. It is possible that we did not retrieve all relevant publications through database searches, given that our search terms were not exhaustive. In addition, we were unable to assess for would be an error to assume all episodes are equivalent between different studies and then combine them in a meta-analysis. An additional limitation in our study is related to the lack of ranking or priority of importance of clinical signs, thus all were considered equivalent.
Finally, several changes were made to the protocol during the performance of the review. Most of these changes were related to outcomes extracted from experimental studies, after it was determined that no single gold standard for determining B. burgdorferi infection status in dogs exists. 18 Unfortunately, we were unable to perform planned subgroup analyses of commercially available vaccines, which would have provided the most clinically relevant information to practicing veterinarians. As previously discussed, linking current commercial availability with commercial availability at the time of publication was deemed necessary and would likely not be possible because of proprietary rights of vaccine companies.
| CONCLUSIONS
This review suggests that dogs vaccinated for Lyme disease have a lower odds of developing clinical signs than unvaccinated dogs, based on experimental studies with deliberate disease exposure. However, there were a number of limitations with regard to these studies and included small sample sizes, potential bias related to random sequence generation and blinding, and an unverified assumption of exposure of all dogs to infected ticks. The authors acknowledge that there are many challenges associated with studying Lyme disease in dogs, from a lack of reproducible disease model and gold standard method to determine infection status, to the low frequency of clinical signs in infected dogs. 6, 18 Ideally, a meta-analysis would have been performed to assess vaccine efficacy in field conditions; however, we were unable to perform a meta-analysis for observational studies because only 2 of 3 eligible studies provided raw data for noncritical outcomes (seroconversion). No experimental field trials were identified by our study, highlighting a major gap in the literature on this topic. In addition to improvements in study design, future studies should focus on larger sample sizes in field conditions to provide the most relevant information for clinical practice. 
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FIGURE 7
Funnel plot of the meta-analysis of published studies for the lameness outcome in experimental studies. Each plotted point represents the standard error and log odds ratio for unique cases of lameness in dogs vaccinated for Lyme disease compared to control dogs. The white triangle represents the region where 95% of the data points would lie in the absence of a publication bias
